Physician profile
Kenneth Merchant
NPI 1669621546
$5,958.00
in general payments reported to CMS, 2019-2025
34 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $228 · 2021: $278 · 2022: $949 · 2023: $1,342 · 2024: $1,599 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,314.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,313.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,403.10 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $709.69 | 2022-2025 | |
| Amgen INC. | $585.99 | 2022-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $505.28 | 2022-2024 | Spravato |
| Lilly USA, LLC | $443.42 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.16 | 2020-2025 | Jardiance |
| Boston Scientific Corporation | $267.77 | 2021-2024 | Watchman Flx |
| Abbott Laboratories | $239.52 | 2022-2025 | Proclaim, Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $226.02 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $201.33 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $159.33 | 2020-2023 | Gardasil 9, Vaxneuvance |
| Abbvie INC. | $136.10 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $127.41 | 2024 | |
| Glaxosmithkline, LLC. | $124.99 | 2025 | Arexvy |
| Pfizer INC. | $111.79 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $51.21 | 2025 | |
| Scilex Pharmaceuticals INC. | $48.23 | 2019 | |
| Astellas Pharma US INC | $26.61 | 2024 | Veozah |
| Medtronic, INC. | $25.01 | 2023 | Kyphon Express II Kyphopak Tray |
| Impulse Dynamics (USA) INC. | $24.10 | 2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $21.28 | 2022 | |
| Inspire Medical Systems, INC. | $19.16 | 2024 | Inspire |
| Eisai INC. | $17.82 | 2020 | |
| Emergent Biosolutions INC. | $16.91 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $16.89 | 2023 | Seglentis |
| Electronic Waveform Lab, INC. | $16.21 | 2025 | |
| Nestle Healthcare Nutrition INC. | $14.53 | 2023 | |
| Axsome Therapeutics, INC. | $14.25 | 2024 | Auvelity |
| Optinose US, INC. | $14.22 | 2024 | |
| Collegium Pharmaceutical, INC. | $14.18 | 2023 | Xtampza |
| Currax Pharmaceuticals LLC | $13.87 | 2025 | Contrave |
| Esperion Therapeutics, INC. | $13.68 | 2025 | Nexletol |
| Lucid Diagnostics INC. | $11.78 | 2022 | |
| Redhill Biopharma INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Merchant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.